Good

Stories that celebrate innovation, and the good side of humanity, to give you hope.

Clinical trial gives hope for soothing agitation

Clinical trial gives hope for soothing agitation

by ALZHEIMER SOCIETY OF CANADA

One in five people with Alzheimer’s disease experience severe agitation.

While extreme restlessness is hard for anyone to bear, in those with dementia it may also speed the progression of the disease. Doctors don’t understand why, but they know that controlling agitation is important.

“It’s a quality of life issue,” says Dr. Krista Lanctôt, a senior researcher at Toronto’s Sunnybrook Research Institute and an expert in neuropsychiatric problems. “When people are agitated and have an inner turmoil, their obvious discomfort is hard to watch.”

Because the number of those with Alzheimer’s disease and other dementias is increasing exponentially, researchers are looking for ways to make the disease easier to live with.

When people are agitated and have an inner turmoil, their obvious discomfort is hard to watch.

That includes controlling agitation. But antipsychotic drugs currently used to treat it work only with some people. These drugs can contribute to cognitive decline in their own right, while also increasing risk of stroke.

That’s why Dr. Lanctôt, with the help of Sunnybrook’s Dr. Nathan Herrmann, is poised to launch a small clinical trial of a drug called nabilone that shows promise for treating agitation, without the side effects of antipsychotic drugs. It could also control pain and the weight loss common in those with Alzheimer’s disease.

Nabilone is a synthetic version of the active ingredient in marijuana plants. Cancer patients use it to treat chemotherapy-induced nausea, and those with anorexia use it to help stimulate appetite and regain weight. But it has never been properly tested in people with Alzheimer’s.

Launching this fall, Dr. Lanctôt’s study is co-funded by the Alzheimer Society Research Program and the Discovery Foundation of Canada.

It involves 40 participants with Alzheimer’s disease. Half will be randomly assigned to take nabilone for six weeks and then a placebo for six weeks, with a week in between when they take neither. The other half will begin with six weeks of placebo, followed by a week off, and then six weeks of nabilone.

Dr. Lanctôt will measure changes in agitation, reported pain and weight gain. If all goes well, she hopes to progress to a larger clinical trial.

No one with dementia should have to suffer severe agitation.

Help the Alzheimer Society of Canada continue to fund this kind of research by giving to the Alzheimer Society Research Program. More information is available at www.alzheimer.ca.



You might also enjoy:

Raising Alzheimer's Awareness with Video Games

Sixty-five isn't old--not when most of us hope to push into…

Touching a Chord

Launched in January 2013, the Music & Memory Project aims to distribute 10,000 iPods to people with…

'Silver Alert' for seniors

Ashlee McGarvey has a great idea about senior safety: Keep our seniors safe by initiating a ‘Silver…

A Tender Alzheimer's Love Story

Ed, my Romanian soulmate of 30 years, had Alzheimer's. And I knew I'd never be able to accept it. It…

comments powered by Disqus